Evista: Advanced Osteoporosis Prevention and Treatment
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.43 | $43.00 (0%) | 🛒 Add to cart |
| 60 | $1.12 | $86.00 $67.08 (22%) | 🛒 Add to cart |
| 90 | $1.01 | $129.00 $91.16 (29%) | 🛒 Add to cart |
| 120 | $0.97 | $172.00 $116.10 (32%) | 🛒 Add to cart |
| 180 | $0.91 | $258.00 $164.26 (36%) | 🛒 Add to cart |
| 270 | $0.88 | $387.00 $237.36 (39%) | 🛒 Add to cart |
| 360 | $0.86
Best per pill | $516.00 $310.46 (40%) | 🛒 Add to cart |
Synonyms | |||
Evista (raloxifene hydrochloride) is a selective estrogen receptor modulator (SERM) specifically engineered for the management and prevention of osteoporosis in postmenopausal women. It offers a targeted therapeutic approach that mimics the beneficial effects of estrogen on bone mineral density without stimulating breast or uterine tissues. Clinically proven to reduce the risk of vertebral fractures, Evista represents a cornerstone in long-term skeletal health strategy, combining efficacy with a well-characterized safety profile. Its dual benefit in lowering invasive breast cancer risk in eligible populations further underscores its role as a multifactorial agent in postmenopausal healthcare.
Features
- Active ingredient: Raloxifene hydrochloride 60 mg
- Administration: Oral tablet
- Pharmacologic class: Selective Estrogen Receptor Modulator (SERM)
- FDA-approved for treatment and prevention of osteoporosis in postmenopausal women
- Also indicated for risk reduction of invasive breast cancer in high-risk postmenopausal women
- Non-hormonal mechanism of action
Benefits
- Significantly increases bone mineral density, reducing fracture incidence
- Lowers risk of new vertebral fractures by approximately 30–50% in treated populations
- Provides breast cancer risk reduction benefit in appropriate patient cohorts
- Avoids estrogen-related stimulation of endometrial tissue
- Offers convenient once-daily dosing supporting long-term adherence
- Demonstrates favorable effects on lipid profiles by lowering LDL cholesterol
Common use
Evista is primarily prescribed for the prevention and treatment of osteoporosis in postmenopausal women. It is also utilized for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis or those at high risk for invasive breast cancer. Healthcare providers may consider Evista particularly for patients who are not candidates for traditional hormone replacement therapy due to contraindications or personal preference.
Dosage and direction
The recommended dosage is one 60 mg tablet orally once daily, with or without food. Patients should take Evista at approximately the same time each day to maintain consistent serum levels. Supplemental calcium and vitamin D intake is advised if dietary intake is inadequate. Treatment duration should be evaluated periodically based on bone mineral density assessments and individual risk factors.
Precautions
Patients should be advised regarding the increased risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Discontinuation at least 72 hours prior to prolonged immobilization is recommended. Use with caution in patients with hepatic impairment. Regular gynecological examinations are recommended due to possible vasomotor symptoms (hot flashes) and leg cramps. Not recommended for premenopausal women.
Contraindications
Evista is contraindicated in women with active or past history of venous thromboembolic events. Additional contraindications include pregnancy, nursing mothers, and women who may become pregnant. Hypersensitivity to raloxifene hydrochloride or any component of the formulation prohibits use. Concomitant use with estrogen-containing products or cholestyramine is not recommended.
Possible side effects
Common adverse reactions include hot flashes, leg cramps, and peripheral edema. Serious side effects may include venous thromboembolism, stroke, and fatal cardiovascular events in certain risk groups. Less frequently reported effects include arthralgia, insomnia, and rash. Patients should report any unusual symptoms, especially calf pain, chest discomfort, or sudden vision changes.
Drug interaction
Concomitant use with warfarin may require prothrombin time monitoring. Cholestyramine reduces absorption and should not be co-administered. Highly protein-bound drugs may compete for binding sites. Use with caution alongside other medications that increase risk of thrombosis, including hormonal therapies.
Missed dose
If a dose is missed, the patient should take it as soon as remembered unless it is nearly time for the next dose. Doubling the dose to catch up is not recommended. Maintain regular dosing schedule thereafter.
Overdose
Limited data exist on human overdose. In clinical trials, doses up to 600 mg/day have been administered. Supportive care is recommended, with attention to possible exacerbation of adverse effects such as flushing and leg cramps. There is no specific antidote.
Storage
Store at controlled room temperature (20–25°C or 68–77°F). Keep in original container, tightly closed, and protect from light and moisture. Keep out of reach of children and pets.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and individualized treatment recommendations. Safety and efficacy may vary based on individual health status and risk factors.
Reviews
Clinical studies demonstrate Evista’s consistent efficacy in fracture risk reduction and bone density improvement. Many practitioners note its valuable niche in patients seeking non-hormonal osteoporosis management. Some patients report manageable vasomotor symptoms, while others appreciate the dual benefit of bone protection and breast cancer risk reduction. Long-term adherence is generally favorable with appropriate patient education and monitoring.